The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …

Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

Therapeutic cancer vaccines are designed to increase tumor-specific T cell immunity.
However, suppressive mechanisms within the tumor microenvironment (TME) may limit T …

Immunotherapy has revolutionized the treatment of patients with cancer. However,
promoting antitumour immunity in patients with tumours that are resistant to these therapies …

Pyroptosis refers to the process of gasdermin-mediated lytic programmed cell death (PCD)
characterized by the release of pro-inflammatory cytokines. Our knowledge of pyroptosis has …

Emerging as a potent anticancer treatment, subcellular targeted cancer therapy has drawn
increasing attention, bringing great opportunities for clinical application. Here, two targeting …

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …